The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmHomie Razavi, Achim Kautz, Imam Waked et al.|Journal of Viral Hepatitis|2014Cited by 484
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitisRong Fan, Jinlin Hou, George Ν. Dalekos et al.|Journal of Hepatology|2020Cited by 346
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trialChristopher Koh, Theo Heller, Laëtitia Canini et al.|The Lancet Infectious Diseases|2015Cited by 262
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)Willem Pieter Brouwer, Qing Xie, Milan J. Sonneveld et al.|Hepatology|2014Cited by 165
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 studyCihan Yurdaydın, Jeffrey S. Glenn, Onur Keskın et al.|Hepatology|2017Cited by 150